Pitching a bio, medtech, or health startup to accelerators and early-stage investors

How evaluators judge therapeutics, medical device, diagnostics, research tool, and digital health startups, and what founders should prepare on data, regulatory path, business model, IP, and follow-on funding.

Larry Chao, PhD, Sovereign Pivot · Last updated October 7, 2026

Life-science and health startups are judged by their own standards. Many programs route them to a separate panel with scientific, clinical, and regulatory expertise, and that panel asks different questions from a general software committee. The question of whether a big company could copy you comes up less often. In its place, evaluators ask whether the data is real, whether the regulatory path is understood, and who will fund the company through the next, much larger round.

This guide is for founders building therapeutics, medical devices, diagnostics, research tools, AI-driven drug discovery, and digital health products. It covers how these pitches are evaluated and what tends to sink them, then sets out what to prepare. It draws on patterns observed across early-stage selection interviews and builds on the general pitch preparation guide.

How bio and health pitches are judged differently

Fundability comes first. Early investors in life sciences know they will not carry a company to market alone. Their first question is often who invests next, at what milestone, and how soon. A strong science story with no credible next funder struggles, and so does a business model investors in the sector rarely back.

Data outweighs vision. Evaluators with research backgrounds ask to see the data early and often. Claims without data shown, or data presented without controls and context, lose ground quickly.

The regulatory path is part of the business plan. Knowing your device class, pathway, and testing requirements is treated as a test of founder competence. Imprecise regulatory language is noticed immediately.

The program horizon matters. Accelerators and seed investors ask what you will de-risk within their time frame. A company whose next meaningful milestone sits years away, or depends on science that cannot be settled in the near term, is often judged too early, however promising.

Talent bets are harder to make. Investors who readily back a strong team in software are more cautious here. A long, regulated development path rewards experience, and a gifted but inexperienced team is often pointed toward an incubator to mature first.

The data

Show the data, early in the pitch, and make it easy to interpret.

Match the data to the claim. Cell-culture or in vitro results support a mechanism claim. Animal data supports an efficacy claim in a model. Human data, even a small study, changes the conversation. State plainly what stage your evidence has reached.
Show controls and comparators. Compare against the current standard of care or the best available alternative, under the same conditions.
Separate a signal from an outcome. Better expression, sensitivity, or detection is an intermediate result. Evaluators will ask whether it improves what matters to patients or customers, and how you will demonstrate the improvement.
Report sample sizes. A result from a handful of patients or samples is useful when presented honestly as early. Presented as definitive, it costs credibility.
Disclose human data you have. Omitting even a single-patient result invites the question of why it was left out.
Be careful with simulation and AI predictions. Computational results need experimental validation, and evaluators will ask for the source of your wet-lab data.

The regulatory path

Prepare a regulatory slide that an expert would accept without correction.

Name the pathway. For devices, state the class and whether you expect a 510(k), De Novo, or premarket approval route, with the predicate device if one exists. For therapeutics, state where the asset is relative to an IND and which trials come next.
Use the words precisely. Cleared, approved, registered, and compliant mean different things, and evaluators listen for the difference. Claiming to be "FDA compliant" when the product is not cleared draws immediate skepticism.
Be consistent about intended use. A product described as both a wellness device and an FDA-cleared diagnostic confuses the room. Decide what you claim, because the claim sets the pathway.
Distinguish prediction from diagnosis. Products that predict a disease event, rather than diagnose a condition, may face a different level of regulatory scrutiny. Show you have thought about it.
List the testing burden. Medical devices face electrical safety, cybersecurity, biocompatibility, and usability testing, and some need a clinical study under an investigational device exemption. Show the testing plan with its cost and timeline.
Name competitors' classifications. If a comparable product went through a stricter pathway, expect to be asked why yours will not.
Cite completed milestones with pride. A regulatory clearance already in hand is one of the strongest signals an early company can show, and evaluators treat it that way.

The business model by segment

Evaluators expect different economics from different kinds of life-science company.

Therapeutics

State the asset's stage clearly. Preclinical, IND-ready, and clinical-stage companies are valued very differently, and a pitch that blurs the stage loses trust.
Show near-term revenue options. Licensing deals or partnerships with pharmaceutical companies can bring revenue sooner and reduce dependence on your own trials. Evaluators who have seen companies struggle to close such deals credit those who have.
Size the raise to the next inflection point. Ask for the amount needed to reach the next value-changing result, and explain why that result moves the valuation. A large raise aimed only at early proof of concept draws questions about focus.
Explain a reformulation or repurposing story fully. Assets built on a previously failed drug need a clear account of what changed and why the new approach will succeed.

Medical devices

Name who pays. Identify the payer, the reimbursement code if one exists, and the economics for the hospital or clinic. Show where the device fits in existing workflows and quality measures.
Show clinical adoption. Getting a new device into a clinic is hard. Explain who uses it, what it replaces, and what it adds to their day.
Address the comparison with consumer devices. Wearables and sensors face the question of why a smartwatch or ring cannot do the same. Have the specific answer.

Diagnostics

Position against the current standard. Name the test you improve on and show where it improves, whether in sensitivity and specificity or in cost and turnaround.
Explain reimbursement and the lab model. Say whether you sell a kit, run a lab service, or license a method, and how each gets paid.
Know the strategic landscape. Diagnostics companies are often acquired by larger platform and testing companies. Naming plausible acquirers, and the data they would need to see, strengthens the case.

Research tools

Show the recurring revenue. Instruments sold once make for a thin business. Consumables, software subscriptions, and service contracts carry the economics.
Size the market realistically. Total research spending in a field is not your market. Count the labs that would buy, at what price, given current funding conditions.

AI drug discovery and computational biology

Show experimental validation. Predictions without wet-lab confirmation are discounted.
Explain the moat beyond expertise. Public datasets and open models are available to every competitor. Name the proprietary data, validation loop, or partnership that others cannot copy.
Be realistic about the model. Pure software or royalty models in drug discovery have a mixed record, and evaluators will ask how you capture value from the molecules you help find.

Digital health and health IT

Treat it as software with extra rules. Expect the software questions on defensibility and buy-versus-build, plus questions on privacy compliance, electronic health record integration, and who in the health system signs the contract.
Name the competitor already inside the hospital. Large health record vendors and established platforms are often the real competition.

IP and ownership

Confirm who owns the IP. University-derived technology needs a license or assignment in place. Patents filed personally, before incorporation, or not yet assigned to the company draw sustained questioning.
Know your freedom to operate. Evaluators will ask whether others' patents block you, especially in crowded therapeutic and diagnostic areas.
Separate filed from granted. State what is pending and what is granted, and in which jurisdictions.
Explain any equity given for resources. Equity exchanged for lab access, licenses, or services early on will be noticed. Show that you understand the dilution.

The team

Pair science with business leadership. A strong scientific team and an impressive advisory board are not enough on their own. Evaluators look for a founder or early hire who can run the company, including raising money and closing partnerships.
Put the right person in the CEO seat. When the most commercially capable founder is not the CEO, evaluators notice, and sometimes say so.
Show regulatory and clinical depth. If no founder has taken a product through regulators, name the advisor or hire who has.
Let more than one founder speak. A full team present while only one person answers leaves the room wondering what the others contribute.
Commit fully. Part-time founders and teams still employed elsewhere face the same skepticism as in any sector.

Market sizing

Life-science market slides are discounted more heavily than most. Build the number from the patients, procedures, labs, or partners you can reach, multiplied by a price someone will pay. Evaluators will check that the serviceable market is plausible for your stage and will say so if a figure looks inflated.

Questions to rehearse

Science and regulatory

What does the data show, against what control, in how many samples or patients?
What stage is the asset or device at, and what is the next milestone?
What is the regulatory pathway, and why that one?
Is the product cleared, approved, or still in development?
What testing remains, and what will it cost?
Does the improved signal change outcomes that matter?

Business and funding

Who pays, and how is it reimbursed?
Who funds the next round, at which milestone?
What can you de-risk within the program or investment period?
Who owns the IP, and do you have freedom to operate?
Who are the likely partners or acquirers, and what would they need to see?
Who on the team leads the business, and who handles regulatory work?

Red flags to avoid

Claims presented without data, or data without controls
Imprecise regulatory language, such as "FDA compliant" for an uncleared product
An intended use that shifts between wellness and medical claims
Unclear asset stage, such as describing a preclinical asset as trial-ready
A raise sized for early proof of concept with no clear inflection point
Research tool economics with no recurring revenue
Market size taken from total sector spending
IP not owned or licensed by the company
A scientific team with no business lead
No credible answer to who funds the next round

Checklist

Key data shown early, with controls, comparators, and sample sizes
Evidence stage stated plainly: in vitro, animal, or human
Regulatory class and pathway named, with predicate or comparable
Testing plan, cost, and timeline for regulatory submission
Intended use stated consistently
Business model matched to segment, with the payer named
Recurring revenue shown for tools and platforms
Raise sized to the next value inflection point
Next funder and milestone identified
Partners and likely acquirers named
IP ownership, licenses, and freedom to operate confirmed
Business lead on the team, with regulatory and clinical depth visible
Market built from reachable customers and real prices
Every founder committed full-time, or a dated plan to get there